VelosBio

United States

Tel: (650) 727-2032

Email: info@velosbio.com

Show jobs for this employer

7 articles with VelosBio

  • Pappas Capital, a leading venture capital firm focused on advancing life sciences, announced that its portfolio company, VelosBio Inc., has entered into a definitive agreement to be acquired by a subsidiary of Merck for $2.75 billion in cash, subject to customary adjustments.

  • Acquisition Strengthens Merck’s Oncology Pipeline with VLS-101, an Investigational Antibody-Drug Conjugate to Treat Hematological Malignancies and Solid Tumors

  • Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.
  • VelosBio Inc . (VelosBio), a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced that the first patient has been dosed in a Phase 2 trial of VLS-101 in patients with solid tumors. VLS-101, the company’s lead product candidate, is an antibody-drug conjugate (ADC) that targets ROR1. ROR1 is a cell-

  • VelosBio Inc . (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the appointment of Paul Bavier as General Counsel. Mr. Bavier will lead all legal and compliance-related functions at the Company. Mr. Bavier has been practicing law for more than 20 years, most of which has

  • VelosBio Inc . (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the appointment of Dr. Enoch Kariuki as Chief Financial Officer. Dr. Kariuki will lead all finance-related and investor relations functions at the Company. Dr. Kariuki is a highly accomplished finance executi

  • Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types Lead investors Matrix Capital Management and Surveyor Capital (a Citadel company) are joined by Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and a